FOLD Stock Analysis Overview
What this means: InvestorsObserver gives Amicus Therapeutics (FOLD) an overall rank of 42, which is below average. Amicus Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 42 means that 58% of stocks appear more favorable to our system.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
FOLD Fundamental Analysis
Upgrade to Premium to unlock Fundamental Ranking
FOLD Short-Term Technical Analysis
Upgrade to Premium to unlock Short-Term Technical Ranking
FOLD Long-Term Technical Analysis
Upgrade to Premium to unlock Long-Term Technical Ranking
FOLD Analyst Ranking
Upgrade to Premium to unlock Analyst Ranking Analysis
FOLD Valuation Ranking Analysis
Upgrade to Premium to unlock Valuation Ranking
FOLD Stock Sentiment Analysis
Upgrade to Premium to unlock Stock Sentiment Ranking
FOLD Stock Analysis Overview
What this means: InvestorsObserver gives Amicus Therapeutics (FOLD) an overall rank of 42, which is below average. Amicus Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 42 means that 58% of stocks appear more favorable to our system.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.